ATE136786T1 - Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor- agonisten - Google Patents

Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor- agonisten

Info

Publication number
ATE136786T1
ATE136786T1 AT90914257T AT90914257T ATE136786T1 AT E136786 T1 ATE136786 T1 AT E136786T1 AT 90914257 T AT90914257 T AT 90914257T AT 90914257 T AT90914257 T AT 90914257T AT E136786 T1 ATE136786 T1 AT E136786T1
Authority
AT
Austria
Prior art keywords
histamine
subject
agent
receptor agonists
analogues
Prior art date
Application number
AT90914257T
Other languages
English (en)
Inventor
Jan Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Syntello Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntello Inc filed Critical Syntello Inc
Application granted granted Critical
Publication of ATE136786T1 publication Critical patent/ATE136786T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90914257T 1989-09-19 1990-09-19 Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor- agonisten ATE136786T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40935789A 1989-09-19 1989-09-19

Publications (1)

Publication Number Publication Date
ATE136786T1 true ATE136786T1 (de) 1996-05-15

Family

ID=23620128

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90914257T ATE136786T1 (de) 1989-09-19 1990-09-19 Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor- agonisten

Country Status (12)

Country Link
US (1) US5348739A (de)
EP (1) EP0493468B1 (de)
JP (1) JP2845622B2 (de)
KR (1) KR100195392B1 (de)
AT (1) ATE136786T1 (de)
AU (1) AU640954B2 (de)
CA (1) CA2066728C (de)
DE (1) DE69026620T2 (de)
DK (1) DK0493468T3 (de)
ES (1) ES2087163T3 (de)
NO (1) NO921050L (de)
WO (1) WO1991004037A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670720A1 (de) * 1992-11-27 1995-09-13 The Wellcome Foundation Limited Enzymhemmer
WO1996005289A1 (en) * 1994-08-08 1996-02-22 Syntello, Inc. Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
WO1999019462A1 (en) 1997-10-10 1999-04-22 The Regents Of The University Of California Enhanced immunogenic cell populations prepared using h2 receptor antagonists
JP2002523378A (ja) * 1998-08-24 2002-07-30 マキシム ファーマシューティカルズ インコーポレイテッド Ｈ２−レセプターアゴニストおよび他のｔ−細胞活性化薬剤を用いたｔ−細胞（ｃｄ４＋およびｃｄ８＋）の活性化および保護
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6153113A (en) 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
EP1200074A2 (de) * 1999-07-16 2002-05-02 Maxim Pharmaceuticals, Inc. Verwendung von diphenyliodonium zur aktivierung und schützung von zytotoxischer lymphozyten
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
EP1536819A4 (de) * 2002-03-29 2007-10-17 Maxim Pharm Inc Nutzung der produktion von reaktiven sauerstoffmetaboliten (rom) und freisetzungshemmern zur behandlung und prävention von intraokularen schäden
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
WO2006039545A2 (en) * 2004-09-30 2006-04-13 Maxim Pharmaceuticals, Inc. Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
WO2006093667A1 (en) 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
BRPI0615096A2 (pt) 2005-08-24 2009-07-14 Inotek Pharmaceuticals Corp análogos de indenoisoquinolinona e métodos de uso dos mesmos
AU2008221358A1 (en) 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
US20120039844A1 (en) * 2009-04-16 2012-02-16 Kristoffer Hellstrand Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formation
US9617517B2 (en) 2011-05-02 2017-04-11 National University Corporation Kumamoto University Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound
WO2019006133A1 (en) * 2017-06-29 2019-01-03 Immune Pharmaceuticals, Inc. METHODS OF DELAYING AND PREVENTING RECHUTE FROM ACUTE MYELOID LEUKEMIA
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
KR920703078A (ko) 1992-12-17
AU640954B2 (en) 1993-09-09
KR100195392B1 (ko) 1999-06-15
JP2845622B2 (ja) 1999-01-13
DE69026620T2 (de) 1996-10-02
DE69026620D1 (de) 1996-05-23
ES2087163T3 (es) 1996-07-16
CA2066728C (en) 2001-12-25
NO921050D0 (no) 1992-03-18
CA2066728A1 (en) 1991-03-20
DK0493468T3 (da) 1996-08-26
EP0493468B1 (de) 1996-04-17
US5348739A (en) 1994-09-20
NO921050L (no) 1992-03-18
AU6419190A (en) 1991-04-18
JPH05504548A (ja) 1993-07-15
EP0493468A1 (de) 1992-07-08
WO1991004037A1 (en) 1991-04-04

Similar Documents

Publication Publication Date Title
ATE136786T1 (de) Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor- agonisten
Stevenson et al. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer.
Goldstein et al. The role of interferon in cancer therapy: a current perspective
Creagan et al. Phase II study of recombinant leukocyte A interferon (rIFN‐αA) in disseminated malignant melanoma
SE7703004L (sv) Hentriakontapeptider och forfarande for deras framstellning
Byfield et al. Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents
DK0683762T3 (da) Acylfulven-analoger som antitumormidler
ATE205400T1 (de) Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii- spezifische mhc allopeptide
ES8502405A1 (es) Un metodo para producir una emulsion acuosa de perfluorocarburo
Pape et al. Kinetics of natural cytotoxicity in patients treated with human fibroblast interferon
FR2699176B1 (fr) Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
Goodman et al. Interleukin-2 and leukemia
Shimizu et al. Effects of a single injection of anti‐asialo GM1 serum on natural cytotoxicity and the growth of a regressive colonic tumor in syngeneic rats
ES2039236T3 (es) Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral.
Masucci et al. Chemotherapy and immunotherapy of colorectal cancer
Gold et al. Autolymphocyte therapy—I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes
Gazit et al. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines
Wang et al. Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin
Betzler et al. Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up
Sporn et al. Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2
Hokland et al. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial
Keong et al. Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells
Robins Purine nucleoside 3′, 5′-cyclic monophosphates as hormonal modulators of cellular proliferation, metastases and lymphocyte response
Voltchek et al. Comparative study of the cytostatic effects of Oliphen and Ukrain
Puri et al. In vivo treatment with interferon causes augmentation of IL‐2 induced lymphokine‐activated killer cells in the organs of mice

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time